Hideaki Ogiwara

National Cancer Centre Japan — Japan

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index4.7kcitations165works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chromatin Remodeling and Cancer(28), DNA Repair Mechanisms(26), Induction Heating and Inverter Technology(24), Advanced DC-DC Converters(21), Multilevel Inverters and Converters(18)

Publications164 total

Supplementary Figure 3 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 1 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 4 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 2 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 5 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 6 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma
npj Precision Oncology·2025· 2 citedOpen Access
Figure 3 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 6 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Figure 6 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Figure 2 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 2 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 4 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Data from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 3 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Figure 4 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 5 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Figure 1 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Supplementary Figure 1 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
Figure 5 from Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
2025Open Access
page 1 of 9Next →

Frequent Co-authors

Takashi Kohno(24), Ayako Ui(12), Takahiro Oike(9), Hiroyasu Tanigawa(8), Masayuki Seki(8), Jun Yokota(7), Takashi Nakano(7), Takemi Enomoto(7), Akira Yasui(6), Hideo Sakasegawa(6), A. Kohyama(6), Mariko Sasaki(5), Reiko Watanabe(5), Koji Tsuta(4), Yoko Shimada(4), Napapat Amornwichet(4), Hitoshi Ichikawa(3), Hiromi Sakamoto(3), Koh Furuta(3), Hirokazu Okayama(3)